The global peripheral vascular devices market, valued at USD 4.7 billion in 2022, is projected to expand at a robust CAGR of 6.6%, reaching USD 8.9 billion by 2032, according to Future Market Insights ...

Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate ...

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce ...

The lawsuit states that Surmodics, Inc. based in Eden Prairie, is the largest provider in the United States of outsourced ...

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Peripheral vascular devices are critical in the treatment of peripheral vascular ... thereby increasing the number of patients requiring medical interventions and driving market growth. Despite these ...

The initial long-term results from EFEMORAL I were presented today by Principal Investigator Prof. Andrew Holden (Auckland ...

R3 Vascular announced that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL ...

Analysts expect Penumbra to report an earnings per share (EPS) of $0.67. The announcement from Penumbra is eagerly ...

BEDFORD, Mass., April 15, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions ...